Building a Human Kinase Gene Repository: Bioinformatics, Molecular Cloning, and Functional Validation

Total Page:16

File Type:pdf, Size:1020Kb

Building a Human Kinase Gene Repository: Bioinformatics, Molecular Cloning, and Functional Validation Building a human kinase gene repository: Bioinformatics, molecular cloning, and functional validation Jaehong Park*, Yanhui Hu*, T. V. S. Murthy*, Fredrik Vannberg*, Binghua Shen*, Andreas Rolfs*, Jessica E. Hutti†, Lewis C. Cantley†, Joshua LaBaer*, Ed Harlow*, and Leonardo Brizuela*‡ *Harvard Institute of Proteomics, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 320 Charles Street, Cambridge, MA 02141; and †Department of Systems Biology, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115 Contributed by Ed Harlow, April 21, 2005 Kinases catalyze the phosphorylation of proteins, lipids, sugars, creation and use of state-of-the-art clone collections that exploit the nucleosides, and other important cellular metabolites and play key newly obtained genome sequence and gene annotation. In the most regulatory roles in all aspects of eukaryotic cell physiology. Here, useful collections, clones would represent fully sequenced-verified we describe the mining of public databases to collect the sequence ORFs, make use of recombination-based cloning techniques, and information of all identified human kinase genes and the cloning be arrayed in high-density formats where all positions are fully of the corresponding ORFs. We identified 663 genes, 511 encoding annotated (16, 17). All these properties will allow high-throughput protein kinases, and 152 encoding nonprotein kinases. We describe (HT) subcloning of the genes in these collections, as well as the successful cloning and sequence verification of 270 of these facilitate experimentation (in any in vivo and in vitro system) and genes. Subcloning of this gene set in mammalian expression data collection͞analysis (both positive and negative data). vectors and their use in high-throughput cell-based screens al- In this study, we describe the construction and proof of principle lowed the validation of the clones at the level of expression and use of such a collection for the human kinase genes. We describe the identification of previously uncharacterized modulators of the the mining of public databases to identify all annotated human survivin promoter. Moreover, expressions of the kinase genes in kinases (including protein and nonprotein kinases) and the gener- bacteria, followed by autophosphorylation assays, identified 21 ation of a sequenced verified clone collection for this gene set by protein kinases that showed autocatalytic activity. The work de- using the CREATOR (BD Biosciences Clontech) cloning platform. scribed here will facilitate the functional assaying of this important We furthermore validated the expression of these clones, success- gene family in phenotypic screens and their use in biochemical and fully screened their activity en masse in three independent cell- structural studies. based assays, and confirmed enzymatic activity for some of those proteins in Escherichia coli. As we demonstrate here, this human kinome ͉ autophosphorylation ͉ cell-based screens ͉ high-throughput kinase clone set will facilitate the study of this important gene class cloning ͉ survivin both in in vivo and in vitro settings. he term kinase refers to a large number of mechanistically, Materials and Methods Tstructurally, and evolutionary distinct classes of enzymes. They Database Mining. To assemble the kinase list, LocusLink informa- catalyze the transfer of the ␥-phosphate from nucleoside triphos- tion was downloaded from the National Center for Biotechnology phates to a large number of molecules, including proteins, sugars, Information web site. Structural Query Language (SQL) was de- nucleosides, and lipids, and affect the activity and fate of those signed to query genes with proper GO͞EXTANNOT annotation, CDD molecules and the cell. annotation, or proper nomenclature. See Supporting Materials and Phosphorylation is a common posttranslational modification of Methods, which is published as supporting information on the proteins and plays a key role on protein structure and function and PNAS web site. in all aspects of cell physiology. Protein kinases contain well conserved motifs and constitute the largest family of proteins in the Molecular Cloning. PCR amplification and cloning was carried out human genome (1–3). Mutations of protein kinases are involved in by using a highly automated and laboratory information manage- carcinogenesis and several other pathological conditions (4–6). ment system (LIMS)-supported pipeline by using CREATOR recom- Phosphorylations of other biomolecules also play a critical role in bination-based cloning technologies (BD Biosciences Clontech) the physiology and pathology of cells. Lipid kinases such as the (see Supporting Materials and Methods). phosphoinositide-3 kinase family members are key modulators of the cellular response to growth factors, hormones, and neurotrans- Generating Expression-Ready Libraries. ORFs were subcloned from mitters and are involved in cancer (7). Nucleotide and nucleoside the pDNR-Dual master vector into mammalian or bacterial ex- kinases regulate the intracellular levels of phosphate donors and pression vectors. For mammalian expression, pLP-CMVneo, pLP- nucleic acid precursors and are involved in the cellular response to EGFP-C1, and pLPS-3ЈEGFP vectors (BD Biosciences Clontech) damage and ischemia (8, 9). Sugar kinases regulate the rates of were chosen for native, N-, and C-terminal EGFP-tagged version sugar metabolism, energy generation, and transcription activation for each kinase, respectively. For bacterial expression, pGEX2tk and are involved in the process of cellular transformation and (Amersham Pharmacia Biotech) was adapted for recombinational apoptosis (10–12). cloning (see Supporting Materials and Methods). The near completion of the Human Genome Project, the ongo- ing annotation projects, and the availability of sequence databases has allowed the genome-scale search and identification of members Abbreviations: HT, high throughput; MGC, Mammalian Gene Collection; shRNA, short- of different gene families by using sequence information as well as hairpin RNA; TCF, T cell factor. structural or functional annotations (2, 3, 13–15). However, a Data Deposition: The gene constructs reported in this paper have been deposited in the systematic cloning, sequence analysis, and functional validation GenBank database (accession nos. AY335555–AY335786). effort for any of these gene sets has been challenging. Indeed, a ‡To whom correspondence should be addressed. E-mail: [email protected]. major goal for experimental biology in this postgenomic era is the © 2005 by The National Academy of Sciences of the USA 8114–8119 ͉ PNAS ͉ June 7, 2005 ͉ vol. 102 ͉ no. 23 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0503141102 Downloaded by guest on September 27, 2021 Table 1. Classification of the human kinase genes identified and efforts. Because of the fact that the information at LocusLink cloning success rate in this study regarding gene sequences and annotations changes rapidly, we Successfully subsequently repeated the query by using 3 LocusLink updates. No. of cloned Success Our most recent version of the human kinase gene set, based Type Group genes genes rate % on the June 2004 analysis, consists of 663 genes. 511 of the genes (77%) encode for protein kinases and 152 genes (23%) for Human kinome 663 270 40.7 nonprotein kinases (Table 1). Genes encoding protein kinases Protein kinase 511 186 36.4 were further classified in groups according to the extended AGC 63 24 38.1 classification of protein kinases (3). Nonprotein kinases com- Atypical 40 13 32.5 prise 23% of all annotated human kinases and are composed of CAMK 73 30 41.1 heterogeneous groups of enzymes from the point of view of CK1 12 7 58.3 substrate specificity, gene sequence, and protein fold (ref. 21; CMGC 62 33 53.2 Gene Ontology Consortium, www.godatabase.org). Data Set 1, RGC 5 0 0.0 which is published as supporting information on the PNAS web Other 78 24 30.8 site, contains all relevant information for each of the 663 STE 45 18 40.0 identified genes. TK 90 22 24.4 Contemporaneous to our initial analysis, Kostich et al. (2) and TKL 43 15 34.9 Manning et al. (3) described the identification of 510 and 518 Nonprotein kinase 152 84 55.3 human genes encoding for protein kinases by using sequence alignments and pair-wise comparisons. Comparison of the data from Manning et al. with our June 2004 search results for the Mammalian Expression and Cell-Based Screens. Cotransfections of protein kinase subset indicates that our current list is missing expression clones and reporter constructs were done by using eight of the genes identified by Manning et al. Seven of these FuGene6 (Roche Molecular Biochemicals) in a 96-well format. genes (SK573, SK581, SK592, SK650, SK681, SK707, and SK723) Reporter activity was measured by using luciferase reporter were associated with LocusLink records that had been retired in assay and Great EscAPe SEAP detection kits (BD Biosciences the June 2004 update. Lastly, SK200 did not have a correspond- Clontech) (see Supporting Materials and Methods). ing full-length GenBank record at the time. The high degree of coverage obtained with these three studies suggests a general Bacterial Expression and Autophosphorylation. For more informa- agreement on the composition of the human protein kinase gene tion on bacterial expression and autophosphorylation, see Sup- family, at least based on available information. porting Materials and Methods. Cloning into Recombinational Plasmid Vectors. We have developed Results and
Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Analysis of the Human Serum Proteome
    Cedarville University DigitalCommons@Cedarville Pharmaceutical Sciences Faculty Publications Department of Pharmaceutical Sciences 6-2004 Analysis of the Human Serum Proteome King C. Chan David A. Lucas Denise Hise Carl F. Schaefer Zhen Xiao See next page for additional authors Follow this and additional works at: https://digitalcommons.cedarville.edu/ pharmaceutical_sciences_publications Part of the Pharmacy and Pharmaceutical Sciences Commons This Article is brought to you for free and open access by DigitalCommons@Cedarville, a service of the Centennial Library. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@Cedarville. For more information, please contact [email protected]. Authors King C. Chan, David A. Lucas, Denise Hise, Carl F. Schaefer, Zhen Xiao, George M. Janini, Kenneth H. Buetow, Haleem J. Issaq, Timothy D. Veenstra, and Thomas P. Conrads Clinical Proteomics Journal Copyright ©Humana Press Inc. All rights of any nature whatsoever are reserved. ISSN 1542-6416/04/01:101–225/$25.00 Serum/Plasma Proteome Analysis of the Human Serum Proteome King C. Chan,1,† David A. Lucas,1,† Denise Hise,2 Carl F. Schaefer,2 Zhen Xiao,1 George M. Janini,1 Kenneth H. Buetow,2 Haleem J. Issaq,1 Timothy D.Veenstra,1 and Thomas P. Conrads1,* 1Laboratory of Proteomics and Analytical Technologies, National Cancer Institute at Frederick, SAIC-Frederick, Inc, PO Box B, Frederick, MD 21702 2Center for Bioinformatics, National Cancer Institute, Bethesda, MD 20892 †These authors contributed equally to this work. each of which was analyzed by microcapillary Abstract reversed-phase liquid chromatography coupled Changes in serum proteins that signal online with MS/MS analysis.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
    YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics Pang-Dian Fana,b,1, Giuseppe Narzisic, Anitha D. Jayaprakashd,2, Elisa Venturinie,3, Nicolas Robinec, Peter Smibertd, Soren Germerf, Helena A. Yug, Emmet J. Jordang,4, Paul K. Paikg, Yelena Y. Janjigiang, Jamie E. Chaftg, Lu Wanga,5, Achim A. Jungblutha, Sumit Middhaa, Lee Spraggona,b,6, Huan Qiaoh, Christine M. Lovlyh, Mark G. Krisg, Gregory J. Rielyg, Katerina Politii, Harold Varmusj,1,7, and Marc Ladanyia,b,1 aDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065; bHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065; cComputational Biology, New York Genome Center, New York, NY 10013; dTechnology Innovation Lab, New York Genome Center, New York, NY 10013; eProject Management, New York Genome Center, New York, NY 10013; fSequencing Operations, New York Genome Center, New York, NY 10013; gDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065; hVanderbilt–Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232; iDepartment of Pathology and the Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520; and jCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065 Contributed by Harold Varmus, May 8, 2018 (sent for review October 12, 2017; reviewed by Levi Garraway and Alice T. Shaw) In ∼30% of patients with EGFR-mutant lung adenocarcinomas quired resistance to first-generation EGFR TKIs, the underlying whose disease progresses on EGFR inhibitors, the basis for ac- mechanisms still remain to be identified.
    [Show full text]
  • Application of a MYC Degradation
    SCIENCE SIGNALING | RESEARCH ARTICLE CANCER Copyright © 2019 The Authors, some rights reserved; Application of a MYC degradation screen identifies exclusive licensee American Association sensitivity to CDK9 inhibitors in KRAS-mutant for the Advancement of Science. No claim pancreatic cancer to original U.S. Devon R. Blake1, Angelina V. Vaseva2, Richard G. Hodge2, McKenzie P. Kline3, Thomas S. K. Gilbert1,4, Government Works Vikas Tyagi5, Daowei Huang5, Gabrielle C. Whiten5, Jacob E. Larson5, Xiaodong Wang2,5, Kenneth H. Pearce5, Laura E. Herring1,4, Lee M. Graves1,2,4, Stephen V. Frye2,5, Michael J. Emanuele1,2, Adrienne D. Cox1,2,6, Channing J. Der1,2* Stabilization of the MYC oncoprotein by KRAS signaling critically promotes the growth of pancreatic ductal adeno- carcinoma (PDAC). Thus, understanding how MYC protein stability is regulated may lead to effective therapies. Here, we used a previously developed, flow cytometry–based assay that screened a library of >800 protein kinase inhibitors and identified compounds that promoted either the stability or degradation of MYC in a KRAS-mutant PDAC cell line. We validated compounds that stabilized or destabilized MYC and then focused on one compound, Downloaded from UNC10112785, that induced the substantial loss of MYC protein in both two-dimensional (2D) and 3D cell cultures. We determined that this compound is a potent CDK9 inhibitor with a previously uncharacterized scaffold, caused MYC loss through both transcriptional and posttranslational mechanisms, and suppresses PDAC anchorage- dependent and anchorage-independent growth. We discovered that CDK9 enhanced MYC protein stability 62 through a previously unknown, KRAS-independent mechanism involving direct phosphorylation of MYC at Ser .
    [Show full text]
  • Methods in and Applications of the Sequencing of Short Non-Coding Rnas" (2013)
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Methods in and Applications of the Sequencing of Short Non- Coding RNAs Paul Ryvkin University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, Genetics Commons, and the Molecular Biology Commons Recommended Citation Ryvkin, Paul, "Methods in and Applications of the Sequencing of Short Non-Coding RNAs" (2013). Publicly Accessible Penn Dissertations. 922. https://repository.upenn.edu/edissertations/922 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/922 For more information, please contact [email protected]. Methods in and Applications of the Sequencing of Short Non-Coding RNAs Abstract Short non-coding RNAs are important for all domains of life. With the advent of modern molecular biology their applicability to medicine has become apparent in settings ranging from diagonistic biomarkers to therapeutics and fields angingr from oncology to neurology. In addition, a critical, recent technological development is high-throughput sequencing of nucleic acids. The convergence of modern biotechnology with developments in RNA biology presents opportunities in both basic research and medical settings. Here I present two novel methods for leveraging high-throughput sequencing in the study of short non- coding RNAs, as well as a study in which they are applied to Alzheimer's Disease (AD). The computational methods presented here include High-throughput Annotation of Modified Ribonucleotides (HAMR), which enables researchers to detect post-transcriptional covalent modifications ot RNAs in a high-throughput manner. In addition, I describe Classification of RNAs by Analysis of Length (CoRAL), a computational method that allows researchers to characterize the pathways responsible for short non-coding RNA biogenesis.
    [Show full text]
  • Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia
    Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia Title Page by Ravi K. Patel Bachelor of Science, University of Minnesota, 2013 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2019 Commi ttee Membership Pa UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE Commi ttee Membership Page This dissertation was presented by Ravi K. Patel It was defended on May 31, 2019 and approved by Qiming (Jane) Wang, Associate Professor Pharmacology and Chemical Biology Vaughn S. Cooper, Professor of Microbiology and Molecular Genetics Adrian Lee, Professor of Pharmacology and Chemical Biology Laura Stabile, Research Associate Professor of Pharmacology and Chemical Biology Thomas E. Smithgall, Dissertation Director, Professor and Chair of Microbiology and Molecular Genetics ii Copyright © by Ravi K. Patel 2019 iii Abstract Src-Family Kinases Play an Important Role in Flt3-ITD Acute Myeloid Leukemia Prognosis and Drug Efficacy Ravi K. Patel, PhD University of Pittsburgh, 2019 Abstract Acute myelogenous leukemia (AML) is a disease characterized by undifferentiated bone-marrow progenitor cells dominating the bone marrow. Currently the five-year survival rate for AML patients is 27.4 percent. Meanwhile the standard of care for most AML patients has not changed for nearly 50 years. We now know that AML is a genetically heterogeneous disease and therefore it is unlikely that all AML patients will respond to therapy the same way. Upregulation of protein-tyrosine kinase signaling pathways is one common feature of some AML tumors, offering opportunities for targeted therapy.
    [Show full text]
  • Anti-Yes1 Picoband Antibody Catalog # ABO12155
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Anti-Yes1 Picoband Antibody Catalog # ABO12155 Specification Anti-Yes1 Picoband Antibody - Product Information Application WB, IHC Primary Accession P07947 Host Rabbit Reactivity Human Clonality Polyclonal Format Lyophilized Description Rabbit IgG polyclonal antibody for Tyrosine-protein kinase Yes(YES1) detection. Tested with WB, IHC-P in Human. Reconstitution Add 0.2ml of distilled water will yield a concentration of 500ug/ml. Anti- YES1 Picoband antibody, ABO12155, Anti-Yes1 Picoband Antibody - Additional Western blottingAll lanes: Anti YES1 Information (ABO12155) at 0.5ug/mlLane 1: SGC Whole Cell Lysate at 40ugLane 2: A549 Whole Cell Lysate at 40ugLane 3: HEPG2 Whole Cell Gene ID 7525 Lysate at 40ugPredicted bind size: Other Names 61KDObserved bind size: 61KD Tyrosine-protein kinase Yes, 2.7.10.2, Proto-oncogene c-Yes, p61-Yes, YES1, YES Calculated MW 60801 MW KDa Application Details Immunohistochemistry(Paraffin-embedded Section), 0.5-1 µg/ml, Human, By Heat<br>Western blot, 0.1-0.5 µg/ml, Human<br> Subcellular Localization Cell membrane. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Anti- YES1 Picoband antibody, Cytoplasm, cytosol. Newly synthesized ABO12155,IHC(P)IHC(P): Human Mammary protein initially accumulates in the Golgi Cancer Tissue region and traffics to the plasma membrane through the exocytic pathway. Anti-Yes1 Picoband Antibody - Background Tissue Specificity Expressed in the epithelial cells of renal Proto-oncogene tyrosine-protein kinase Yes is proximal tubules and stomach as well as an enzyme that in humans is encoded by the Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 hematopoietic cells in the bone marrow and YES1 gene.
    [Show full text]
  • PHKG2, Active (SRP5062)
    PHKG2, active, GST tagged, human PRECISIOÒ Kinase recombinant, expressed in Sf9 cells Catalog Number SRP5062 Storage Temperature –70°C Synonyms: GSD9C Figure 1. SDS-PAGE Gel of Typical Lot Product Description 70–95% (densitometry) PHKG2 is the hepatic and testis isoform of the gamma subunit of phosphorylase kinase. PHKG2 gene contains 10 exons and spans 9.5 kb and maps to chromosome 16p12.1-p11.2.1 Deficiency of PHK, a regulatory enzyme of glycogen metabolism, is responsible for 25% of all cases of glycogen storage disease and is genetically and clinically heterogeneous. Mutations in the PHKG2 gene lead to autosomal liver-specific PHK deficiency (glycogen storage disease IXc) and an increased risk of cirrhosis, and at least 11 PHKG2 mutations have been identified to date.2 Figure 2. Specific Activity of Typical Lot Recombinant, full-length, human PHKG2 was 59–81 nmole/min/mg expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is NM_000294. Recombinant protein stored in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol. Molecular mass: ~70 kDa Purity: 70–95% (SDS-PAGE, see Figure 1) Specific Activity: 59–81 nmole/min/mg (see Figure 2) Precautions and Disclaimer Procedure This product is for R&D use only, not for drug, Preparation Instructions household, or other uses. Please consult the Material Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM Safety Data Sheet for information regarding hazards glycerol 2-phosphate, 25 mM MgCl2, 5 mM EGTA, and and safe handling practices.
    [Show full text]
  • Human Cumulus Cells in Long-Term in Vitro Culture Reflect Differential
    cells Article Human Cumulus Cells in Long-Term In Vitro Culture Reflect Differential Expression Profile of Genes Responsible for Planned Cell Death and Aging—A Study of New Molecular Markers Bła˙zejChermuła 1, Wiesława Kranc 2 , Karol Jopek 3, Joanna Budna-Tukan 3 , Greg Hutchings 2,4, Claudia Dompe 3,4, Lisa Moncrieff 3,4 , Krzysztof Janowicz 2,4, Małgorzata Józkowiak 5, Michal Jeseta 6 , Jim Petitte 7 , Paul Mozdziak 8 , Leszek Pawelczyk 1, Robert Z. Spaczy ´nski 1 and Bartosz Kempisty 2,3,6,9,* 1 Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics and Gynecological Oncology, Poznan University of Medical Sciences, 33 Polna St., 60-535 Poznan, Poland; [email protected] (B.C.); [email protected] (L.P.); [email protected] (R.Z.S.) 2 Department of Anatomy, Poznan University of Medical Sciences, 6 Swiecickiego St., 60-781 Poznan, Poland; [email protected] (W.K.); [email protected] (G.H.); [email protected] (K.J.) 3 Department of Histology and Embryology, Poznan University of Medical Sciences, 6 Swiecickiego St., 60-781 Poznan, Poland; [email protected] (K.J.); [email protected] (J.B.-T.); [email protected] (C.D.); l.moncrieff[email protected] (L.M.) 4 The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK 5 Department of Toxicology, Poznan University of Medical Sciences, 30 Dojazd St., 60-631 Poznan, Poland; [email protected] 6 Department of Obstetrics and Gynecology, University Hospital and
    [Show full text]
  • HEY1 Functions Are Regulated by Its Phosphorylation at Ser-68
    Biosci. Rep. (2016) / 36 / art:e00343 / doi 10.1042/BSR20160123 HEY1 functions are regulated by its phosphorylation at Ser-68 Irene Lopez-Mateo*,´ Amaia Arruabarrena-Aristorena†, Cristina Artaza-Irigaray‡, Juan A. Lopez´ §, Enrique Calvo§ and Borja Belandia*1 *Department of Cancer Biology, Instituto de Investigaciones Biomedicas´ Alberto Sols, CSIC-UAM, Arturo Duperier 4, 28029 Madrid, Spain †Proteomics Unit, CIC bioGUNE, Bizkaia Technology Park, 48160 Derio, Spain ‡Division´ de Inmunolog´ıa, Centro de Investigacion´ Biomedica´ de Occidente – IMSS, Sierra Mojada 800, 44340 Guadalajara, Jalisco, Mexico §Unidad de Proteomica, Centro Nacional de Investigaciones Cardiovasculares, CNIC, 28029 Madrid, Spain Synopsis HEY1 (hairy/enhancer-of-split related with YRPW motif 1) is a member of the basic helix–loop–helix-orange (bHLH-O) family of transcription repressors that mediate Notch signalling. HEY1 acts as a positive regulator of the tumour suppressor p53 via still unknown mechanisms. A MALDI-TOF/TOF MS analysis has uncovered a novel HEY1 regulatory phosphorylation event at Ser-68. Strikingly, this single phosphorylation event controls HEY1 stability and function: simulation of HEY1 Ser-68 phosphorylation increases HEY1 protein stability but inhibits its ability to enhance p53 transcriptional activity. Unlike wild-type HEY1, expression of the phosphomimetic mutant HEY1-S68D failed to induce p53-dependent cell cycle arrest and it did not sensitize U2OS cells to p53-activating chemotherapeutic drugs. We have identified two related kinases, STK38 (serine/threonine kinase 38) and STK38L (serine/threonine kinase 38 like), which interact with and phosphorylate HEY1 at Ser-68. HEY1 is phosphorylated at Ser-68 during mitosis and it accumulates in the centrosomes of mitotic cells, suggesting a possible integration of HEY1-dependent signalling in centrosome function.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]